The 2 analysts offering 12-month price forecasts for Celyad Oncology SA have a median target of 5.40, with a high estimate of 8.00 and a low estimate of 2.80. The median estimate represents a +269.98% increase from the last price of 1.46.
The current consensus among 3 polled investment analysts is to Buy stock in Celyad Oncology SA. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.27
Reporting Date Aug 05
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.